Paul Morgan

Caretrust REIT Inc (NASDAQ: CTRE) represents a strong investment opportunity for income-oriented small-cap investors seeking dividend growth, Canaccord Genuity analysts said while reaffirming their Buy rating on the stock. Canaccord says the REIT's low payout ratio of 55 percent provides an...

Canaccord's Paul Morgan has initiated coverage on QTS Realty Trust Inc (NYSE: QTS) with a $63 price target and a Buy rating. Enterprises and government agencies have become extremely open to cloud IT architectures and the "breadth of QTS service offerings, from custom data centers to...

Canaccord's Paul Morgan reiterated Sabra Health Care REIT (NASDAQ: SBRA)'s Hold rating with a price target of $23. Sabra announced Tuesday it will sell its Forest Park Dallas, which Morgan praised. "Sabra has been working on realizing its "Texit" for months, and today...

Shares of Biomed Realty Trust Inc (NYSE: BMR) have declined 11.81 percent year-to-date. Canaccord Genuity’s Paul Morgan has upgraded the company from Hold to Buy, while raising the price target from $21 to $23. Reports of possible M&A are expected to bring investor focus to...

In a report published Monday, MLV & Co analyst Paul Morgan reiterated a Hold rating on Kimco Realty Corporation (NYSE: KIM), and raised the price target from $24.00 to $26.00. In the report, MLV & Co noted, "We are raising our PT to $26 (from $24) to reflect rolling forward our NAV per...

In a report published Monday, MLV & Co analyst Paul Morgan reiterated a Buy rating on American Assets Trust (NYSE: AAT), and raised the price target from $41.00 to $42.00. In the report, MLV & Co noted, “We are raising our price target to $42 from $41, based on rolling forward our NOI...

MLV & Co. downgraded AmREIT Inc (NYSE: AMRE) from Buy to Hold in a report issued Wednesday with a $25 price target. Analysts Paul Morgan and Joe Ng noted that with "shares of AMRE up 50 percent since March and recent reports of a potential sale nearing (in the $25-26 range vs. our $25...

MLV & Co. upgraded American Assets Trust, Inc. (NYSE: AAT) from Hold to Buy and raised its price target from $38 to $41 in a report issued Wednesday. Analysts Paul Morgan and Joe Ng suggested "catalysts over the next few quarters for AAT include: 1) pricing data points support a higher...

In a report published Tuesday, MLV & Co analyst Paul Morgan reiterated a Buy rating and $31.00 price target on Sabra Health Care REIT (NASDAQ: SBRA). In the report, MLV & Co noted, “Sabra's $550M portfolio acquisition of 21 private-pay, Holiday Retirement communities weighed on SBRA shares...

In a report published Friday, MLV & Co analyst Paul Morgan reiterated a Buy rating and $20.00 price target on DDR Corp (NYSE: DDR). In the report, MLV & Co noted, “After the close, DDR announced that CEO Dan Hurwitz will be leaving the firm, as the Board and Mr. Hurwitz ‘have agreed not to...

In a report published Monday, MLV & Co analyst Paul Morgan reiterated a Buy rating on AmREIT (NYSE: AMRE), and raised the price target from $24.00 to $25.00. In the report, MLV & Co noted, “Following AmREIT's 2Q14 report, we are raising our price target to $25 from $24, based on rolling...

In a report published Monday, MLV & Co analyst Paul Morgan reiterated a Hold rating on Equity One (NYSE: EQY), and raised the price target from $23.00 to $24.00. In the report, MLV & Co noted, “Following Equity One's 2Q14 report, we are raising our price target to $24 from $23, based on...

In a report published Tuesday, MLV & Co analyst Paul Morgan reiterated a Hold rating on Simon Property Group (NYSE: SPG), and raised the price target from $178.00 to $186.00. In the report, MLV & Co noted, “Following Simon Property's 2Q14 report, we are raising our price target to $186 from...

In a note dated June 26, MLV & Co. analyst Paul Morgan initiated coverage on the Healthcare REIT Sector with a neutral view due to the balance of "attractive investment opportunities" and risks from a "rising interest rate environment." Within the sector, Morgan says...

In a report published Tuesday, MLV & Co analyst Paul Morgan initiated coverage on AmREIT (NYSE: AMRE) with a Buy rating and $21.00 price target. In the report, MLV & Co noted, “AmREIT's ‘Irreplaceable Corner' shopping center investment strategy targets high-traffic, infill assets located...